ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
- None.
- None.
Insights
The recent findings from the clinical trials involving the ReStore Exo-Suit signify a notable advancement in post-stroke rehabilitation technology. The statistically significant improvements in walking speed and distance are critical endpoints in stroke recovery, as they directly correlate with a patient's independence and quality of life. Such outcomes not only endorse the efficacy of the ReStore Exo-Suit but also suggest a potential shift in the standard of care for stroke rehabilitation.
From a medical research perspective, the persistence of improved walking metrics four weeks post-intervention is particularly compelling. This indicates that the ReStore Exo-Suit may facilitate long-term neuroplastic changes, which are essential for sustained recovery. Furthermore, the emphasis on propulsion mechanics highlights the device's ability to target specific deficits in stroke survivors, potentially leading to more individualized and effective rehabilitation strategies.
The positive outcomes reported for the ReStore Exo-Suit could have significant implications for the healthcare industry, especially in the context of rehabilitation services. The ability of the Exo-Suit to maintain improvements post-intervention could reduce the overall duration and intensity of therapy needed, potentially lowering healthcare costs and increasing the throughput of rehabilitation facilities.
In terms of market impact, Lifeward's active engagement with CMS for determining a final payment amount for the ReWalk Personal Exoskeleton indicates a strategic move towards securing reimbursement pathways. This is a critical step for market penetration and could set a precedent for future technology-based rehabilitation devices. The mention of a next-generation product pipeline also suggests a long-term growth strategy that could appeal to investors looking for companies at the forefront of innovation in medical technology.
The clinical trial results for the ReStore Exo-Suit are likely to resonate positively with investors, given the potential for product adoption and market expansion. The demonstrated clinical value and the durable improvements post-intervention could lead to increased demand for the Exo-Suit, thereby driving revenue growth for Lifeward. Moreover, the company's experience in establishing Medicare coverage for its ReWalk Exoskeleton bodes well for the ReStore Exo-Suit's commercialization strategy.
Investors should closely monitor the company's progress with CMS regarding payment amounts, as favorable outcomes could significantly enhance Lifeward's financial position. The dual focus on advancing clinical outcomes and expanding reimbursement coverage reflects a comprehensive approach to market leadership in the rehabilitation space, which could be a key driver of long-term shareholder value.
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy.
Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded.
Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline.
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation.
“We are encouraged by the tremendous clinical value we see in the ReStore Exo-Suit technology and its ability to retrain and augment propulsion for individuals recovering from stroke,” stated Larry Jasinski, CEO at Lifeward. “We believe these recent studies can broaden the use of robotic therapy in the rehabilitation of patients post-stroke and speak to the potential value of the next generation of products for home use in our development pipeline which are based upon the same ReStore technology. We expect that the experience and infrastructure that we have developed for establishing Medicare coverage of the ReWalk Exoskeleton will also facilitate patients’ access to our future technologies. In parallel, we continue to work actively with CMS to determine a final payment amount for the ReWalk Personal Exoskeleton using the current pricing information we submitted in November 2023.”
The most recent publication, from the University of Pécs in Hungary, titled “Investigation of the Effectiveness of the Robotic ReStore Soft Exoskeleton in the Development of Early Mobilization, Walking, and Coordination of Stroke Patients: A Randomized Clinical Trial” examined key walking metrics for two groups of post-stroke patients, randomized to either a conventional therapy program or a program which included training with the ReStore Exo-Suit. The ReStore intervention group demonstrated significant improvements compared to the control group, including a
A second study from Boston University was presented in an abstract titled “Durable Improvements in Post-Stroke Walking Speed and Distance Following High-Intensity Training with Soft Robotic Exosuits.” This study demonstrated that a 4-week program of intensive gait training with the ReStore Exo-Suit for individuals post-stroke (N=25) resulted in clinically meaningful increases in walking speed (average: 0.17 m/s) and walking distance (34.4 m) which endured a month after the individual had completed the training program. These improvements in speed and distance were accompanied by significant improvements in propulsion mechanics of the paretic limb.
To learn more about the Lifeward mission and product portfolio, please visit GoLifeward.com.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity systems, the ReStore Exo-Suit, and the MyoCycle FES Systems.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.
ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding the Company’s future performance and future regulatory interactions and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Lifeward Media Relations:
LifeSci Communications
E: media@golifeward.com
Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward
E: ir@golifeward.com
FAQ
What were the key findings of the University of Pécs study on the ReStore Exo-Suit for post-stroke patients?
What did the study from Boston University demonstrate regarding the ReStore Exo-Suit?
What did Larry Jasinski, CEO of Lifeward, say about the ReStore Exo-Suit technology?
